** Shares of Rovi ROVI.MC fall 13.5% after lowering its 2026 operating revenue growth guidance
** The Spanish pharma company now expects 2026 revenue to grow at a low- to mid-single-digit rate vs previous guidance for high single-digit to low double-digit growth
** Renta4 expects a negative reaction to the guidance downgrade, which compares to its 8.6% growth forecast for Rovi's 2026 operating revenue
** Shares are the top fallers on Madrid's blue-chip IBEX 35 .IBEX and on track for their biggest daily drop since Feb 2025
(Reporting by Joao Manuel Mauricio)
((JoaoManuel.VicenteMauricio@thomsonreueters.com))